News: Moderna’s technical director says when the vaccine will arrive in Europe and the United States

This Monday it was known that Moderna has developed a vaccine against coronavirus with an efficacy of 94.5%. Juan Andres, Director of Technical Operations and Quality of the pharmaceutical company, gave an interview to Antena 3 Noticias and announced that the vaccine could arrive in Spain in early 2021.

“We’re pending to sign a contract with the European Union and when this happens, and we receive the approval of the European Medicines Agency, we will be ready to start supplying. This can occur as soon as in early 2021. We’re going to have two distinct supply chains, one in the United States and one in Europe for the international community “.

Publication in scientific journals

Asked why vaccine results have not been published in scientific journals, the manager pointed out in the aforementioned medium that the data was communicated to him yesterday: “The committee that follows the clinical trial It is an external committee with experts and it communicated it to us yesterday Sunday.

“These dates they will be published in scientific journals. At this moment what we are doing is giving these data to the health authorities, which are those who have to approve the product to go on the market “Andres added.

Regarding the side effects that some volunteers have suffered, revealed that “are mild or moderate in nature. And the grade 3 effects, which are the most severe, are injection site pain, pain in body, joints, headaches “.

Trust in the vaccine

Later, he went through the microphones of Cadena Ser, where he explained that in principle, the distribution will be made through Rovi in ​​Spain and the Lonza company from Switzerland. In addition, he was overwhelming with the efficacy of the vaccine: “I will put it on myself, my wife, my children and my parents. I would tell the people that there is less left and that they trust.”

In the same station he confirmed that the remedy is effective among the most vulnerable people: Of course. We made a great effort to ensure that the people who were represented in the trial were vulnerable people. Of the 95, 15 of them are over 65. We include people with diverse ethnicities, so that it can be a fairly faithful representation of the social diversity “.